Cargando…

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population

Somatic mutations of MET gene are emerging as important driver mutations for lung cancers. To identify the common clinicopathological features of MET exon 14 skipping mutations and amplification and clarify whether the two MET gene alterations cause protein overexpression were investigated using 196...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lung, Jrhau, Hung, Ming-Szu, Lin, Yu-Ching, Lee, Kam-Fai, Jiang, Yuan Yuan, Huang, Shao-Lan, Fang, Yu-Hung, Lu, Ming-Shian, Lin, Chin-Kuo, Yang, Tsung-Ming, Lin, Paul Yann, Hsieh, Meng-Jer, Tsai, Ying Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675391/ https://www.ncbi.nlm.nih.gov/pubmed/31369639 http://dx.doi.org/10.1371/journal.pone.0220670

Ejemplares similares

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
por: Liu, Xue-wen, et al.
Publicado: (2020)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Lung, Jrhau, et al.
Publicado: (2020)

Author Correction: A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Lung, Jrhau, et al.
Publicado: (2021)

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
por: Gow, Chien-Hung, et al.
Publicado: (2023)

Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products
por: Lung, Jrhau, et al.
Publicado: (2020)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
por: Zheng, Difan, et al.
Publicado: (2016)

Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
por: Chai, Rui‐Chao, et al.
Publicado: (2021)

ExonSkipDB: functional annotation of exon skipping event in human
por: Kim, Pora, et al.
Publicado: (2020)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Betel Nut Chewing Increases the Risk of Metabolic Syndrome and Its Components in a Large Taiwanese Population Follow-Up Study Category: Original Investigation
por: Huang, Ya-Chin, et al.
Publicado: (2022)

In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically
por: Lung, Jrhau, et al.
Publicado: (2017)

Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
por: Hung, Ming-Szu, et al.
Publicado: (2019)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Classifying Included and Excluded Exons in Exon Skipping Event Using Histone Modifications
por: Chen, Wei, et al.
Publicado: (2018)

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
por: Jiao, Yang, et al.
Publicado: (2021)

Natural Exon Skipping Sets the Stage for Exon Skipping as Therapy for Dystrophic Epidermolysis Bullosa
por: Bremer, Jeroen, et al.
Publicado: (2019)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Combinatorial Pattern of Histone Modifications in Exon Skipping Event
por: Chen, Wei, et al.
Publicado: (2019)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
por: Lau, Sally C.M., et al.
Publicado: (2023)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Non-small cell lung cancer with MET exon 14 skip mutation: case report
por: Clough, Wolfgang, et al.
Publicado: (2022)

MET exon 14 skipping is overexpressed in an allele-specific manner in lung adenocarcinoma primary samples
por: Durham, Megan, et al.
Publicado: (2023)

Clinical Implications of FADD Gene Amplification and Protein Overexpression in Taiwanese Oral Cavity Squamous Cell Carcinomas
por: Chien, Huei-Tzu, et al.
Publicado: (2016)

Association and Interaction between Heavy Metals and Hyperuricemia in a Taiwanese Population
por: Lu, Lu-Heng, et al.
Publicado: (2023)

Therapeutic exon skipping for dysferlinopathies?
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2010)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Lipid Droplets in Lung Cancers Are Crucial for the Cell Growth and Starvation Survival
por: Lung, Jrhau, et al.
Publicado: (2022)

Influences of Satisfaction with Telecare and Family Trust in Older Taiwanese People
por: Tsai, Chung-Hung, et al.
Publicado: (2014)

A compatible exon-exon junction database for the identification of exon skipping events using tandem mass spectrum data
por: Mo, Fan, et al.
Publicado: (2008)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7f4fnocheu74nf09c4f52tm6ih